Snag a bestselling car vac at its lowest price this year, plus more of today's best deals
You may be in the thick of spring cleaning, but there's one place you may have forgotten: your car. Luckily, you can snag the bestselling ThisWorx car vacuum for just $22 today — the lowest price it's been all year. This handy gadget will suck up any dirt, Dorito dust, dog hair or pretzel crumbs that may be lurking in your ride. If your tires need a little love, you can snag this popular tire inflator for its lowest price ever. Don't have a car? No worries: There are tons of other great deals right now, including Tory Burch sandals for over 40% off, an Amazon Fire tablet for over 30% off and a Kate Spade crossbody for just $82 — 75% off! Hop to it and snag these killer deals (and more!) while you can.
Adidas: Get up to 40% off sale shoes and apparel.
Coach Outlet: Save up to 70% on sale styles.
Cozy Earth: Get up to 30% off Oprah-approved bedding and pajamas during the Mother's Day Sale.
Everlane: Get up to 75% off sale styles.
Kate Spade Outlet: Get up to 75% off everything.
Loft: Take 40% off your entire purchase.
Nordstrom: Shop thousands of sale items for up to 80% off.
Nordstrom Rack: Save up to 70% on thousands of new markdowns.
Old Navy: Score 30-50% off almost everything on the site.
Spanx: Get up to 40% off select AirEssentials sale items, and up to 70% off sale items.
Sur La Table: Save up to 60% on top brands like Staub, Le Creuset and more.
Target: Snag marked-down Easter accessories and get up to 40% off select vacuums.
Walmart: Shop rollbacks and flash deals of up to 80% off.
Wayfair: Stock up on patio tables and chairs for up to 50% off during the Big Outdoor Sale.
If you have Amazon Prime, you'll get free shipping, of course. Not yet a member? No problem. You can sign up for your free 30-day trial here. (And by the way, those without Prime still get free shipping on orders of $35 or more.)
The reviews quoted above reflect the most recent versions at the time of publication.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNBC
3 hours ago
- CNBC
Best Stocks: Three healthcare names to ponder including a biotech back to levels not seen in a decade
(This is The Best Stocks in the Market , brought to you by Josh Brown and Sean Russo of Ritholtz Wealth Management.) Josh here — The healthcare sector has entered the chat. There are 12 healthcare names now on our Best Stocks list as of the end of last week. I'll show you a few of these set-ups below and then Sean's going to share some fundamentals for these healthcare firms. Sector Leaderboard As of 6/9/2025 morning, there are 114 names on The Best Stocks in the Market list Top Sector Ranking: Top Industries: Top 5 Best Stocks by Relative Strength: Sector Spotlight: Healthcare Josh — Alnylam Pharma (ALNY) just broke out above prior resistance at $300. There was company-specific news about new indications for one of their most important drugs that led to multiple price target raises on The Street. Alnylam is named for Alnilam, the brightest star in the Belt of Orion constellation, which ancient mariners used for navigation. The founders of the company believed their trailblazing work in the field of RNA interference (RNAi) would chart a brand new course of drug discovery and development by which the next generation of scientists would be guided. So far, so good as ALNY grew revenue to $2.25 billion in revenue last year and the company's market cap swelled to a respectable $40 billion. Wall Street's median price target is ten percent higher than today's price while the most bullish analyst, H.C. Wainwright, just published a target of $500 this past week. In Q1 2025, revenue surged by over 28% year-over-year to approximately $594 million, driven largely by the strength of the TTR franchise. Looking ahead, analysts project revenue growth of 24–33% through 2025–2026, supported by improving EPS and an expected annual revenue of $2.9 billion. The company also maintains a strong balance sheet, with around $223 million in free cash flow, a quick ratio of approximately 2.7×, and increasing support from major institutional investors who are adding to their positions. (data via Reuters) Sean — AMVUTTRA (vutrisiran) was recently FDA‑approved for cardiomyopathy, expanding its market from neuropathy, which is a major catalyst for the stock — it significantly expands its addressable market beyond its original use for polyneuropathy. This approval allows Alnylam to target patients with transthyretin amyloid cardiomyopathy (ATTR-CM), a much larger population than those with ATTR polyneuropathy. The drug's unique RNA interference mechanism and dosing schedule (quarterly or biannual injections) give it a competitive edge over existing therapies like Pfizer's Vyndaqel. This dual-indication approval not only boosts Alnylam's revenue potential but also strengthens its path toward profitability, making AMVUTTRA a key growth driver for the company and a pivotal reason for recent momentum. Josh — Allow for short-term consolidation in the $300 area, await the next catalyst. 50-day crossing over 200-day important signal that a new uptrend could be forming. Cardinal Health Josh — All three major Pharmaceutical Wholesalers made the list - McKesson (MCK) , Cencora (COR) and Cardinal Health (CAH) , only Cardinal looks good technically right now: CAH held its 50-day on a weekly closing basis during the April bloodbath, I'd use that area as a stop and update it each week. If the uptrend breaks, there's no reason to be long. Sean — CAH is a $37 billion wholesaler, sourcing and distributing branded, generic, and specialty pharmaceutical products to pharmacies, hospitals, and healthcare providers. All three names on our list, Cardinal, Cencora, and McKesson, hold well over 90% of the US pharmaceutical wholesale industry. CAH trades at an 18x forward PE and a 15x P/FCF - this thing is generating cash for investors. It has a 1.3% dividend yield and is growing earnings 8% this year, and is expected to grow its earnings 12% next year. Gilead Sciences Josh — Gilead (GILD) , as you can see in the chart above, is not done going up. This name has been on the list for most of the year so far. At the market lows this spring, it never violated its upward-sloping 200-day moving average — didn't even pay it a visit. And just for fun, below is the "forever" chart back to the company's IPO. I am a believer that price has memory, but I'm not sure there are still a lot of shareholders hanging around here from the last time it traded near the $120 level a decade ago. That said, I wouldn't be surprised to see a battle at that old high as new shareholders buy from sellers who are just thrilled to be getting out break-even. That's what makes a market. Sean — Gilead Sciences (GILD) has been on a run. Its experimental HIV prevention shot, lenacapavir, showed near-complete effectiveness in trials and is expected to generate $2–4 billion in peak annual sales—potentially transforming the HIV prevention market. The company has also posted solid financial results, with 2024 revenue and earnings rising due to strong performance in its HIV, liver disease, and oncology franchises. Analysts have raised price targets across the board, reflecting increased confidence in the company's pipeline and execution. GILD has a meaningful run rate of free cash flow (~$9.6B) and a growing pipeline of drugs for the future. DISCLOSURES: (None) All opinions expressed by the CNBC Pro contributors are solely their opinions and do not reflect the opinions of CNBC, NBC UNIVERSAL, their parent company or affiliates, and may have been previously disseminated by them on television, radio, internet or another medium. THE ABOVE CONTENT IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY . THIS CONTENT IS PROVIDED FOR INFORMATIONAL PURPOSES ONLY AND DOES NOT CONSITUTE FINANCIAL, INVESTMENT, TAX OR LEGAL ADVICE OR A RECOMMENDATION TO BUY ANY SECURITY OR OTHER FINANCIAL ASSET. THE CONTENT IS GENERAL IN NATURE AND DOES NOT REFLECT ANY INDIVIDUAL'S UNIQUE PERSONAL CIRCUMSTANCES. THE ABOVE CONTENT MIGHT NOT BE SUITABLE FOR YOUR PARTICULAR CIRCUMSTANCES. BEFORE MAKING ANY FINANCIAL DECISIONS, YOU SHOULD STRONGLY CONSIDER SEEKING ADVICE FROM YOUR OWN FINANCIAL OR INVESTMENT ADVISOR. INVESTING INVOLVES RISK. EXAMPLES OF ANALYSIS CONTAINED IN THIS ARTICLE ARE ONLY EXAMPLES. THE VIEWS AND OPINIONS EXPRESSED ARE THOSE OF THE CONTRIBUTORS AND DO NOT NECESSARILY REFLECT THE OFFICIAL POLICY OR POSITION OF RITHOLTZ WEALTH MANAGEMENT, LLC. JOSH BROWN IS THE CEO OF RITHOLTZ WEALTH MANAGEMENT AND MAY MAINTAIN A SECURITY POSITION IN THE SECURITIES DISCUSSED. ASSUMPTIONS MADE WITHIN THE ANALYSIS ARE NOT REFLECTIVE OF THE POSITION OF RITHOLTZ WEALTH MANAGEMENT, LLC" TO THE END OF OR OUR DISCLOSURE. Click here for the full disclaimer.
Miami Herald
3 hours ago
- Miami Herald
Tariff impact on grocery prices muted so far, Circana reports
Tariffs have yet to make a noticeable impact on retail grocery prices this year, with inflation in the sector in 2025 driven primarily by supply constraints unrelated to levies on imports, according to a May 30 report from Circana. Food and beverage prices were up 2.9% on a year-over-year basis as of the end of the week of May 18, Circana reported. Prices were up 1.7% in 2024. Price increases this year have mostly stemmed from tight supplies of eggs, meat, coffee and cocoa, with coffee costs still going up even as prices for the other categories have stabilized, Circana said. The Trump administration announced a broad array of tariffs shortly after taking office, but temporarily paused many of the levies. U.S. officials have indicated that they intend to reinstate tariffs on imports from countries the government is unable to hammer out trade deals with during the pause. The United States Court of International Trade last month issued an injunction blocking many of the executive orders that authorized the tariffs, but the ruling was put on hold by a federal appeals court. While tariffs have not played a meaningful role in pushing up food and beverage prices in recent months, Circana noted that certain categories, including seafood, produce, alcohol and baking ingredients, are more susceptible to potential cost increases than others due to their high reliance on imports. By contrast, items such as dairy products, most meats, shelf-stable breakfast foods and frozen meals depend more heavily on domestic supply chains, making them less susceptible to potential tariff-related impacts, Circana noted. Food and beverage volumes were off by about half a percent in May after growing slightly during the first quarter and the final three months of 2024, Circana said, attributing the decline to cooler weather, relatively weak consumer sentiment and reduced demand following strong Easter sales. Circana said it expects volumes for the sector to grow slightly as 2025 continues. Copyright 2025 Industry Dive. All rights reserved.
Yahoo
4 hours ago
- Yahoo
Dilon Technologies, Inc. Closes $9 Million in Growth Capital Financing
NEWPORT NEWS, Va., June 9, 2025 /PRNewswire/ -- Dilon Technologies®, a global leader in medical devices for biosurgery and breast cancer treatment and diagnosis, today announced a $9 million growth capital investment from JGB Management Inc. The investment will support Dilon's continued double-digit revenue growth and operational scaling. Dilon Technologies has built a robust presence in surgical settings with a portfolio of products that improve clinical outcomes. "We are proud to partner with JGB as we advance our mission to deliver evidence-based surgical solutions worldwide," said George Makhoul, CEO of Dilon Technologies. "This funding empowers us to continue delivering best-in-class innovations that improve patient care." HEMOBLAST Bellows® is a groundbreaking advanced hemostatic agent used in a wide range of surgeries—including cardiac, general, and orthopedic procedures. It remains the only FDA-approved product specifically indicated for the control of minimal, mild, and moderate bleeding. Now utilized in several hundred U.S. hospitals, HEMOBLAST® Bellows continues to redefine standards in surgical hemostasis. Another key product, MarginProbe® an in-surgery, real-time breast cancer margin assessment device. It enables surgeons to assess lumpectomy margins intraoperatively, significantly reducing the need for repeat surgeries. Clinical studies show MarginProbe® reduces re-excision rates by 25% to 80%. A 2025 study published in The American Surgeon Journal highlighted a 42% reduction in re-excision for patients with DCIS. A next-generation version of the device has been submitted to the FDA, with approval anticipated by year-end. Dilon's Navigator™ Gamma Probe product line, a market-leading tool for radio-guided lymphatic mapping and tumor localization, continues to perform strongly worldwide. A new, enhanced version is expected to launch by late 2025. "We are pleased to partner with Dilon Technologies to help them grow in their mission to provide surgical solutions worldwide," said Brett Cohen, CEO of JGB Management Inc. For more information, visit About Dilon Technologies® Technologies® Inc. is a commercial-stage medical device company that develops, manufactures, and markets innovative technologies used in hemostasis, cancer detection and assessment, and airway management. Dilon's growing surgical portfolio includes: HEMOBLAST Bellows®: The only FDA-approved powder-form hemostatic agent for minimal, mild, and moderate bleeding. MarginProbe®: A groundbreaking real-time margin assessment tool for breast cancer surgery. Navigator™ System: A leading surgical gamma probe for tumor localization and lymphatic mapping. TrueView 100 Pro: A surgical specimen analyzer for intraoperative use. CoPilot VL+®: A compact, portable video laryngoscope for airway visualization. About JGB Management Inc. JGB Management Inc., founded by Brett Cohen in 2005, is an alternative asset management firm focused on investing in niche credit-oriented situations. JGB specializes in privately negotiated investments. The firm is based in Westport CT. View original content to download multimedia: SOURCE Dilon Technologies Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
